Nelivaptan

Nelivaptan (INN)[1] (developmental codename SSR-149,415) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype.[2] The drug had entered clinical trials for treatment of anxiety and depression.[3] In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.[4]

Nelivaptan
Clinical data
Routes of
administration		Oral
ATC code
  • none
Identifiers
IUPAC name
  • (2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxo-indolin-3-yl]-4-hydroxy-N,N-dimethyl-pyrrolidine-2-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.210.987
Chemical and physical data
FormulaC30H32ClN3O8S
Molar mass630.11 g·mol−1
InChI
  • InChI=1S/C30H32ClN3O8S/c1-32(2)28(36)24-15-19(35)17-33(24)30(21-8-6-7-9-25(21)41-4)22-14-18(31)10-12-23(22)34(29(30)37)43(38,39)27-13-11-20(40-3)16-26(27)42-5/h6-14,16,19,24,35H,15,17H2,1-5H3/t19-,24+,30+/m1/s1 Y
  • Key:NJXZWIIMWNEOGJ-WEWKHQNJSA-N Y
 NY (what is this?)  (verify)

See also

References
  1. World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information. 21 (4): 341.
  2. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). "Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders". Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370–5. Bibcode:2002PNAS...99.6370G. doi:10.1073/pnas.092012099. PMC 122955. PMID 11959912.
  3. Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). "An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders". CNS Drug Reviews. 11 (1): 53–68. doi:10.1111/j.1527-3458.2005.tb00035.x. PMC 6741711. PMID 15867952.
  4. "Second-quarter 2008 results" (PDF). Press Release. Sanofi-Aventis. 2008-07-31. Archived from the original (PDF) on 2008-12-06. Retrieved 2009-06-10. It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).
  • SSR149415 at the US National Library of Medicine Medical Subject Headings (MeSH)


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.